The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Subjects aged ≥ 18 years.
ECOG Performance Status ≤ 2.
Histologically confirmed MCL or MZL, including EMZL/MALT lymphoma, SMZL, and NMZL.
Have received at least two prior lines of systemic therapy and do not have FDA approved available therapies or have refused them.
Prior receipt of FGFR inhibitor.
Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.
Concurrent anticancer therapy except as listed in section 6.7.2 for prostate and breast cancer.
Cytotoxic chemotherapy within 4 weeks prior to treatment.
University of Utah
Lead sponsor
Incyte Corporation
Collaborator